Burden of pulmonary arterial hypertension in Germany.
This study aimed to describe health care provision, resource consumption and related costs, as well as treatment patterns and quality of life in adult patients with pulmonary arterial hypertension (PAH) in Germany. Data for this retrospective and prospective cost-of-illness-study were derived from hospitals, general practitioners and patients. Costs were evaluated from the perspective of third party payer and patient. Quality of life data were collected by using three validated instruments. A total of 167 patients were enrolled at 10 hospitals. Time period from first occurrence of symptoms to confirmed diagnosis of PAH was 2.3 years on average. Mean number of GP visits was 1.5 per patient per month, and within 15 months, inpatient stays were reported for 50% of patients. The ratio of combination therapy to single-drug therapy for endothelin receptor antagonists, phosphodiesterase-5-inhibitor and prostacyclin analogues increased significantly during 15 months. Treatment costs were, on average, euro47,400 per patient per year, arising mainly from drugs. Compared to the general population, quality of life of PAH patients was considerably impaired. This is the first study which evaluated aspects of the medical and economic consequences of PAH based on a large cohort of PAH patients in Germany.
Department of Pneumology, Universitätsklinikum des Saarlandes/Homburg, Kirrberger Strasse 1, 66424 Homburg/Saar, Germany. heinrike.wilkens@uks.eu
H
H
Wilkens
F
F
Grimminger
M
M
Hoeper
G
G
Stähler
B
B
Ehlken
C
C
Plesnila-Frank
K
K
Berger
A
A
Resch
A
A
Ghofrani
D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D005260:Female; D005858:Germany / Q000453:epidemiology; D005102:Health Expenditures; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D012189:Retrospective Studies
D010726:Phosphodiesterase Inhibitors